Zhao, Sizheng Steven 
ORCID: 0000-0002-3558-7353, Harrison, Stephanie R, Chan, Antoni, Clarke, Nick, Davis, Charlotte, Eddison, Joe, Gregory, William J, Jones, Gareth T, Marzo-Ortega, Helena, Murphy, Daniel J et al (show 7 more authors)
(2023)
Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope.
RHEUMATOLOGY ADVANCES IN PRACTICE, 7 (2).
rkad039-.
Abstract
Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | AS, Axial spondyloarthritis, biologic, biosimilar, IL17, JAK inhibitor, switching, tapering, treat-to-target |
| Divisions: | Faculty of Health and Life Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 06 Feb 2024 11:10 |
| Last Modified: | 06 Feb 2024 11:10 |
| DOI: | 10.1093/rap/rkad039 |
| Open Access URL: | https://doi.org/10.1093/rap/rkad039 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3178502 |
Dimensions
Dimensions
